Startup B2LAB is bringing a fresh wave to the medical sector with a “dental implant fixture” that applies an eco-friendly surface treatment technology based on femtosecond lasers. Although the company is small in size, it is making steady progress with low-cost, environmentally friendly technology. The question is what lies behind B2LAB’s success.

Differentiation through unparalleled technological capabilities

Founded in May 2021, B2LAB’s core technology is implant surface treatment using femtosecond lasers. A femtosecond laser has an extremely short pulse width of one-quadrillionth (1/1,000,000,000,000,000) of a second, enabling ultra-precise microfabrication to the extent that it is used in ophthalmic LASIK surgery. The company has also developed a high-speed femtosecond laser surface treatment technology to further differentiate itself.


Conventional dental implants are surface-treated using a chemical process involving strong acid. This process requires a massive amount of cleaning solution and inevitably raises environmental pollution issues. B2LAB addresses this problem with eco-friendly surface treatment using femtosecond lasers. According to B2LAB, the implants are not only safe and clean but also feature strong and rapid osseointegration.

In 2023, B2LAB obtained the world’s first domestic approval from the Ministry of Food and Drug Safety for a femtosecond laser surface-treated dental implant fixture (LASERO). This achievement is significant not just as a simple product approval but as the creation of a new technology category. In fact, in 2024, a new mid-classification item, “dental implant fixture–LASER treated,” was added to the National Health Insurance reimbursement schedule. The creation of a new category in the insurance system means that the innovativeness of the technology has been institutionally recognized.

‘Meaningful results’ up to research paper publication

Femtosecond laser surface treatment is fast and simple to clean, making it possible to automate all processes. As no industrial waste is generated from the surface treatment, it also enables the establishment of eco-friendly processes and systems. This leads to not only improved quality but also cost reduction, enhancing price competitiveness.

These eco-friendly attributes are even more favored overseas. In 2024, B2LAB received positive responses by participating in dental equipment exhibitions held in Dubai and Vietnam. In 2025, the company obtained medical device approval from the Thai Food and Drug Administration, securing a foothold for expansion into Southeast Asia, and it also participated in “IDS 2025,” the world’s largest dental equipment exhibition held in Cologne, Germany.


Furthermore, in October 2025, B2LAB published a paper in the internationally renowned journal “Advanced Functional Materials,” announcing research results that “nano-wave surfaces improve the osseointegration rate compared to conventional surfaces.” The company was the first to elucidate the mechanism by which this technology goes beyond simply roughening the surface to alter the morphology of cell nuclei and regulate gene expression, thereby promoting bone regeneration. Animal experiments also demonstrated meaningful outcomes, confirming an osseointegration effect at a level comparable to that of conventional sandblasted, large-grit, acid-etched (SLA) surfaces.

In particular, this paper signifies that B2LAB has achieved world-class research results in the field of materials science and engineering. It also helped raise B2LAB’s profile in the medical community. Follow-up studies are currently underway.

Six experts with different specializations

B2LAB was founded by a team of six, centered on CEO Jung Bo-soo and CTO Lee Byung-hak, who had been researching femtosecond laser technology at the Korea Electrotechnology Research Institute (KERI). CEO Jung’s expertise spans electronic engineering, biomedical engineering, systems biology, and dental biomaterials science, while CTO Lee is a specialist in mechanical engineering and optics. Their combined expertise forms a core asset that underpins B2LAB’s technological strength.

CEO Jung stressed, “Typically, medical device companies require a large workforce due to various regulatory requirements. B2LAB has secured high-level approvals with a minimum number of employees.” He added, “Although all staff members share a background in science and engineering, each has a different major. Everyone faithfully performs their roles in their respective positions. There have been no resignations so far, and even the most recently hired employee is now in their fifth year with the company.”


The organizational culture at B2LAB, which has had no resignations since its founding, is rooted in the idea of enjoyment. As employees spend more time with colleagues than with their families, CEO Jung and all staff members strive to make working hours enjoyable. In such an atmosphere, opinions can be expressed freely, which naturally leads to strong performance.

In the early stages of the startup, CEO Jung focused on building internal strength rather than securing large-scale investment. By operating on a small scale, the company was able to make quick decisions in line with strategy shifts and customer feedback, which in turn contributed to reinforcing its technological capabilities and invigorating its organizational culture. This has been the foundation for B2LAB’s solid growth.

Focusing on promoting the excellence of K-implants

In 2026, B2LAB will continue to accelerate its push into overseas markets. Following participation in “CES 2026,” the world’s largest consumer electronics and IT exhibition, the company will also attend “AEEDC 2026,” the Middle East’s largest dental equipment exhibition. In particular, B2LAB earned an invitation to CES 2026 not for conventional consumer electronics technology, but in recognition of the innovativeness and scalability of its eco-friendly surface treatment technology. Through this, the company sees a full-fledged global trend emerging in which medical device surface treatment is also transitioning to non-chemical, eco-friendly processes. At AEEDC, B2LAB was selected for the startup pavilion again in 2026 following 2024, after fierce competition, thereby reaffirming both its technological strength and market potential.


B2LAB has obtained Class C medical device approvals in Thailand, Indonesia, and Vietnam. Class C devices are medium-to-high risk medical devices that include equipment and implants that come into long-term contact with the human body or that sustain or support life. The company is currently in the process of obtaining approvals in the United States (FDA Class II) and Brazil (ANVISA Class III).

CEO Jung stated, “We expect to obtain approvals from the U.S. FDA and Brazil’s ANVISA in 2026, which will enable full-scale overseas expansion. We are also preparing for domestic eco-friendly certifications.”

Having completed the build-out of its expert workforce, secured technological capabilities, and formulated a global expansion strategy, B2LAB is striving to enhance the status of K-implants. By combining Korean-style implants with the differentiating technology of femtosecond lasers, the company has expressed its determination to leap forward as a technology-leading enterprise active on the global stage.

IT Donga, reporter Park Gui-im (luckyim@itdonga.com)

Popular News